{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:29:15Z","timestamp":1792218555438,"version":"4.4.0"},"reference-count":121,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/19420862.2020.1860476","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:54:59Z","timestamp":1610934899000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":291,"title":["Antibodies to watch in 2021"],"prefix":"10.1080","volume":"13","author":[{"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"first","affiliation":[{"name":"Institut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"The Antibody Society, Inc., Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1415671"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1269580"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1125583"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.988944"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29282"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27333"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24990"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22976"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.1.18719"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13895"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.1.10677"},{"key":"cit0014","unstructured":"Celltrion Healthcare. Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms. November 5, 2020 press release. Accessed November 6, 2020. www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=409&pagenumber=1&keyword=&keyword_type="},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"cit0016","unstructured":"Regeneron. Regeneron\u2019s COVID-19 outpatient trial prospectively demonstrates that REGN-COV2 antibody cocktail significantly reduced virus levels and need for further medical attention. October 28, 2020 press release. Accessed November 6, 2020. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regenerons-covid-19-outpatient-trial-prospectively-demonstrates"},{"key":"cit0017","unstructured":"Food and Drug Administration. Bamlanivimab Emergency Use Authorization letter dated November 9, 2020. Accessed November 10, 2020. www.fda.gov\/media\/143602\/download"},{"key":"cit0018","unstructured":"Eli Lilly and Company. Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19. October 28, 2020 press release. Accessed November 6, 2020. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-agreement-us-government-supply-300000-vials"},{"key":"cit0019","unstructured":"Eli Lilly and Company. CEO Dave Ricks shares Lilly\u2019s principles of COVID-19 antibody therapy pricing and access. October 28, 2020 press release. Accessed November 6, 2020. https:\/\/www.lilly.com\/news\/stories\/dave-ricks-covid19-antibody-therapy-pricing-access"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z"},{"key":"cit0021","unstructured":"Food and Drug Administration. Casirivimab and imdevimab Emergency Use Authorization letter dated November 21, 2020. Accessed November 22, 2020. https:\/\/www.fda.gov\/media\/143891\/download"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1583"},{"key":"cit0023","unstructured":"Cytodyn, Inc. CytoDyn announces clinically significant top-line results from its phase 2 trial in mild-to-moderate COVID-19 patients. August 11, 2020 press release. Accessed November 6, 2020. https:\/\/www.cytodyn.com\/investors\/news-events\/press-releases\/detail\/458\/cytodyn-announces-clinically-significant-top-line-results."},{"key":"cit0024","unstructured":"Biocad. A drug against COVID-19 complications is registered in Russia. June 11, 2020 press release. Accessed October 26, 2020. https:\/\/biocadglobal.com\/post\/Levilimab."},{"key":"cit0025","unstructured":"Biocon. Biocon presented insights into clinical study that enabled DCGI approval of itolizumab for COVID-19. July 13, 2020 press release. Accessed October 26, 2020. www.biocon.com\/biocon-presented-insights-into-clinical-study-that-enabled-dcgi-approval-of-itolizumab-for-covid19\/."},{"key":"cit0026","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Clinical review, application number 761143Orig1s000. Accessed September 22, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761143Orig1s000MedR.pdf"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264671"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"cit0030","unstructured":"Sanofi. FDA approves Sarclisa\u00ae (isatuximab-irfc) for patients with relapsed refractory multiple myeloma. March 2, 2020 press release. Accessed September 14, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-03-02-19-51-16."},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253450"},{"key":"cit0032","unstructured":"Sanofi. Sarclisa\u00ae (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma. May 12, 2020 press release. Accessed September 14, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-05-12-07-00-00."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115"},{"key":"cit0034","unstructured":"US Food and Drug Administration. FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments. April 22, 2020 press release. Accessed September 14, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments."},{"key":"cit0035","unstructured":"Immunomedics, Inc. Immunomedics announces positive results from Phase 3 ASCENT study of TRODELVY\n                      TM\n                      . July 6, 2020 press release. Accessed September 14, 2020. https:\/\/www.immunomedics.com\/our-company\/news-and-events\/immunomedics-announces-positive-results-from-phase-3-ascent-study-of-trodelvytm\/."},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"cit0037","unstructured":"Bio V. Viela Bio announces U.S. FDA approval of UPLIZNA\u2122 (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). June 11, 2020 press release. Accessed September 22, 2020. https:\/\/ir.vielabio.com\/news-releases\/news-release-details\/viela-bio-announces-us-fda-approval-upliznatm-inebilizumab-cdon."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"cit0040","unstructured":"MorphoSys AG FDA approves Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). August 1, 2020 press release. Accessed September 11, 2020. https:\/\/www.morphosys.com\/media-investors\/media-center\/fda-approves-monjuvir-tafasitamab-cxix-in-combination-with-lenalidomide."},{"key":"cit0041","unstructured":"GlaxoSmithKline. FDA approves GSK\u2019s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma. August 2, 2020 press release. Accessed September 12, 2020. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma\/."},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"cit0043","unstructured":"Helwick C Responses achieved with belantamab mafodotin in relapsed or refractory myeloma. The ASCO Post, July 10, 2020. Accessed November 7, 2020. https:\/\/ascopost.com\/issues\/july-10-2020\/responses-achieved-with-belantamab-mafodotin-in-relapsed-or-refractory-myeloma\/."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"cit0046","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment for Ebola virus. October 14, 2020 press release. Accessed October 15, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus."},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"cit0048","unstructured":"Y-mAbs Therapeutics, Inc. FDA approves Y-mAbs\u2019 DANYELZA\u00ae (naxitamab-gqgk) for the treatment of neuroblastoma. November 25, 2020 press release. Accessed November 26, 2020. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/fda-approves-y-mabs-danyelzar-naxitamab-gqgk-treatment."},{"key":"cit0049","unstructured":"Y-mAbs Therapeutics, Inc. Y-mAbs announces naxitamab update. October 25, 2019 press release. Accessed September 19, 2020. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-naxitamab-update"},{"key":"cit0050","unstructured":"Y-mAbs Therapeutics, Inc. Y-mAbs announces update on naxitamab and omburtamab in neuroblastoma. October 16, 2020 press release. Accessed November 7, 2020. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-update-naxitamab-and-omburtamab-neuroblastoma."},{"key":"cit0051","unstructured":"Biocad. New drug for melanoma treatment got approved. June 15, 2020 press release. Accessed September 20, 2020. https:\/\/biocadglobal.com\/index.php?posts&post=52."},{"issue":"11","key":"cit0052","volume":"30","author":"Tjulandin S","year":"2019","journal-title":"Annal Oncol"},{"key":"cit0053","unstructured":"R-Pharm Group. R-Pharm has registered Artlegia (olokizumab). May 29, 2020 press release. Accessed September 20, 2020. http:\/\/r-pharm.com\/en\/press-center\/news\/467."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa037"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153801"},{"key":"cit0056","unstructured":"Macrogenics, Inc. MacroGenics provides update on FDA review of margetuximab for HER2-positive metastatic breast cancer. May 28, 2020 press release. Accessed September 20, 2020. http:\/\/ir.macrogenics.com\/news-releases\/news-release-details\/macrogenics-provides-update-fda-review-margetuximab-her2."},{"key":"cit0057","volume-title":"Presented at: 2019 San Antonio Breast Cancer Symposium"},{"key":"cit0058","volume-title":"MacroGenics presents results from the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer at the San Antonio Breast Cancer Symposium","author":"Macrogenics, Inc","year":"2019"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216296"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004215"},{"key":"cit0061","unstructured":"Biogen Inc., Eisai, Co., Ltd. FDA accepts Biogen\u2019s aducanumab biologics license application for Alzheimer\u2019s disease with priority review. August 7, 2020 press release. Accessed September 8, 2020. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-accepts-biogens-aducanumab-biologics-license-application."},{"key":"cit0062","unstructured":"Biogen. Update on FDA advisory committee\u2019s meeting on aducanumab in Alzheimer\u2019s disease. November 6, 2020 press release. Accessed November 7, 2020. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-fda-advisory-committees-meeting-aducanumab-alzheimers."},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13497"},{"key":"cit0068","unstructured":"Omeros Corporation. Omeros reports final efficacy and safety data from the narsoplimab pivotal trial in HSCT-TMA. October 22, 2020 press release. Accessed November 7, 2020. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-reports-final-efficacy-and-safety-data-narsoplimab."},{"key":"cit0069","unstructured":"Provention Bio, Inc. Provention Bio reports second quarter 2020 financial results and provides business update. August 6, 2020 press release. Accessed September 8, 2020. http:\/\/investors.proventionbio.com\/2020-08-06-Provention-Bio-Reports-Second-Quarter-2020-Financial-Results-and-Provides-Business-Update."},{"key":"cit0070","unstructured":"ElsaLys Biotech. ELSALYS BIOTECH announces submission of biologics license application to FDA for LEUKOTAC\u00ae (inolimomab) for the treatment of graft-versus-host disease in adult patients. July 23, 2020 press release. Accessed September 9, 2020. https:\/\/www.elsalysbiotech.com\/node\/113."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028282"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"cit0073","volume-title":"American Academy of Dermatology 2020 Annual Meeting (Virtual)","author":"Reich K"},{"key":"cit0074","unstructured":"UCB. First presentations of bimekizumab Phase 3 data demonstrate superior skin clearance over placebo and Stelara\u00ae at week 16 in adults with moderate-to-severe plaque psoriasis. June 12, 2020 press release. Accessed September 22, 2020. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/First-Presentations-of-Bimekizumab-Phase-3-Data-Demonstrate-Superior-Skin-Clearance-Over-Placebo-and-Stelara-at-Week-16-in-Adults-with-Moderate-to-Severe-Plaque-Psoriasis."},{"key":"cit0075","unstructured":"UCB. Bimekizumab Phase 3 psoriasis study demonstrates superiority versus Humira[\u00ae]. December 6, 2019 press release. Accessed September 22, 2020. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-Phase-3-Psoriasis-Study-Demonstrates-Superiority-Versus-Humira."},{"key":"cit0076","unstructured":"UCB. Bimekizumab superior to Cosentyx[\u00ae] in achieving complete psoriasis skin clearance. July 24, 2020 press release. Accessed September 22, 2020. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-Superior-to-Cosentyx-in-Achieving-Complete-Psoriasis-Skin-Clearance."},{"key":"cit0077","unstructured":"Sesen Bio. Sesen Bio reports positive, preliminary data update from Phase 3 VISTA trial for high-risk non-muscle invasive bladder cancer. August 8, 2020 press release. Accessed September 14, 2020. https:\/\/ir.sesenbio.com\/news-releases\/news-release-details\/sesen-bio-reports-positive-preliminary-data-update-phase-3-vista."},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65483-2"},{"key":"cit0079","volume-title":"Presented at: 2020 ESMO Virtual Congress"},{"key":"cit0080","unstructured":"Agenus Inc. Agenus presents results from two large cervical cancer trials at ESMO. September 18, 2020 press release. Accessed September 21, 2020. https:\/\/investor.agenusbio.com\/news-releases\/news-release-details\/agenus-presents-results-two-large-cervical-cancer-trials-esmo."},{"key":"cit0081","unstructured":"ADC Therapeutics SA. ADC Therapeutics submits biologics license application to the U.S. Food and Drug Administration for loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma. September 21, 2020 press release. Accessed September 22, 2020. https:\/\/ir.adctherapeutics.com\/press-releases\/press-release-details\/2020\/ADC-Therapeutics-Submits-Biologics-License-Application-to-the-U.S.Food-and-Drug-Administration-for-Loncastuximab-Tesirine-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma\/default.aspx."},{"key":"cit0082","volume-title":"25th Congress of the European Hematology Association (Virtual)","author":"Carlo-Stella C","year":"2020"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261"},{"key":"cit0084","unstructured":"AstraZeneca. Year-to-date and Q3 2020 results. Accessed November 11, 2020. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2020\/q3\/Year-to-date_and_Q3_2020_results_Conferences_and_roadshows.pdf."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"cit0086","unstructured":"Sanofi. Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease. December 10, 2019 press release. Accessed November 14, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-12-10-13-30-00."},{"key":"cit0087","unstructured":"Sanofi. FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease. November 14, 2020 press release. Accessed November 14, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-11-14-01-00-00."},{"key":"cit0088","unstructured":"CytoDyn Inc. Update on HIV-BLA-PDUFA. July 13, 2020 press release. Accessed November 7, 2020. https:\/\/www.cytodyn.com\/investors\/news-events\/press-releases\/detail\/449\/update-on-hiv-bla-pdufa-fda-requested-more-information-to."},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13815-w"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1638"},{"key":"cit0092","unstructured":"Regeneron Pharmaceuticals, Inc. Regeneron announces encouraging garetosmab Phase 2 results in patients with ultra-rare debilitating bone disease. January 9, 2020 press release. Accessed September 25, 2020. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-announces-encouraging-garetosmab-phase-2-results."},{"key":"cit0093","unstructured":"Regeneron Pharmaceuticals, Inc. Regeneron reports second quarter 2020 financial and operating results. August 5, 2020 press release. Accessed September 25, 2020. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-reports-second-quarter-2020-financial-and-operating."},{"key":"cit0094","unstructured":"Y-mAbs Therapeutics, Inc. Y-mAbs provides regulatory update on omburtamab for the treatment of patients with neuroblastoma. October 5, 2020 press release. Accessed November 7, 2020. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-provides-regulatory-update-omburtamab-treatment-patients."},{"key":"cit0095","unstructured":"Y-mAbs Therapeutics, Inc. Y-mAbs announces positive omburtamab clinical data. October 29, 2019 press release. Accessed\u00a0November\u00a07, 2020. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-positive-omburtamab-clinical-data."},{"key":"cit0096","unstructured":"Byondis BV Synthon Biopharmaceuticals relaunches as Byondis. April 16, 2020 press release. Accessed September 26, 2020. https:\/\/www.byondis.com\/who-we-are\/press-releases\/synthon-biopharmaceuticals-rebranded-as-byondis."},{"key":"cit0097","unstructured":"Genmab and Seattle Genetics. Genmab and Seattle Genetics present data from tisotumab vedotin innovaTV 204 pivotal trial in recurrent or metastatic cervical cancer at ESMO Virtual Congress 2020. September 21, 2020 press release. Accessed September 25, 2020. https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-and-seattle-genetics-present-data-tisotumab-vedotin."},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0116"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9512"},{"key":"cit0100","unstructured":"TG Therapeutics, Inc. TG Therapeutics provides business update and reports second quarter 2020 financial results. August 10, 2020 press release. Accessed September 28, 2020. https:\/\/ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-provides-business-update-and-reports-second-0."},{"key":"cit0101","unstructured":"TG Therapeutics, Inc. TG Therapeutics announces positive topline results from the UNITY-CLL Phase 3 study evaluating the combination of umbralisib and ublituximab (U2) for the treatment of patients with chronic lymphocytic leukemia. May 5, 2020 press release. Accessed September 28, 2020. https:\/\/ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-announces-positive-topline-results-unity-cll."},{"key":"cit0102","volume-title":"TG Therapeutics announces final results of the GENUINE Phase 3 study evaluating ublituximab plus ibrutinib in previously treated high-risk chronic lymphocytic leukemia at the 56th American Society of Clinical Oncology Annual Meeting (Virtual)","year":"2020"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8022"},{"key":"cit0104","unstructured":"Novartis Pharmaceuticals Corporation. Reimagining AML & MDS: targeting immune and myeloid cells for dual impact. Accessed September 28, 2020. https:\/\/www.virtualcongress.novartis.com\/eha25\/myeloid\/aml-and-mds\/."},{"key":"cit0105","unstructured":"Agenus Inc. Agenus announces ESMO oral presentation of two clinical trials of balstilimab alone and in combination with zalifrelimab in recurrent or metastatic cervical cancer. August 26, 2020 press release. Accessed October 2, 2020. https:\/\/investor.agenusbio.com\/news-releases\/news-release-details\/agenus-announces-esmo-oral-presentation-two-clinical-trials."},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27398"},{"key":"cit0107","unstructured":"argenx BV. argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110). December 2, 2018 press release. Accessed October 2, 2020. https:\/\/www.argenx.com\/news\/argenx-enters-exclusive-global-collaboration-and-license-agreement-cilag-gmbh-international."},{"key":"cit0108","unstructured":"Janssen Pharmaceutical Companies of Johnson & Johnson. Selected NME pharmaceutical pipeline as of July 16, 2020. Accessed October 1, 2020. https:\/\/www.investor.jnj.com\/pharmaceutical-pipeline."},{"key":"cit0109","unstructured":"Akeso Inc. 2020 Interim presentation, August 2020. Accessed September 29, 2020. https:\/\/www.akesobio.com\/media\/1306\/akeso-2020-interim-results-presentation.pdf."},{"key":"cit0110","unstructured":"China International Capital Corporation Limited. Akeso Inc. Equity Research, July 7, 2020. Accessed September 29, 2020. http:\/\/pdf.dfcfw.com\/pdf\/H3_AP202007081390358126_1.pdf."},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00292"},{"key":"cit0112","unstructured":"Checkpoint Therapeutics, Inc. September 2020 corporate presentation. Accessed September 27, 2020. https:\/\/s2.q4cdn.com\/326900168\/files\/doc_presentations\/2020\/09\/v2\/Checkpoint-Presentation_CKPT_September-2020_2.pdf."},{"key":"cit0113","unstructured":"Checkpoint Therapeutics, Inc. Checkpoint Therapeutics announces positive interim results from registration-enabling trial of cosibelimab in metastatic cutaneous squamous cell carcinoma. September 17, 2020 press release. Accessed September 27, 2020. https:\/\/ir.checkpointtx.com\/press-releases\/news-details\/2020\/Checkpoint-Therapeutics-Announces-Positive-Interim-Results-from-Registration-Enabling-Trial-of-Cosibelimab-in-Metastatic-Cutaneous-Squamous-Cell-Carcinoma\/default.aspx"},{"key":"cit0114","unstructured":"ImmunoGen, Inc. Form 10-K for the year ended December 31, 2019. Accessed September 26, 2020. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/855654\/000155837020002399\/imgn-20191231x10kd363eb.htm."},{"key":"cit0115","volume-title":"Actinium announces two oral presentations featuring data and findings from the Phase 3 SIERRA trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting (Virtual)","author":"Actinium Pharmaceuticals, Inc","year":"2020"},{"key":"cit0116","volume-title":"Alphamab Oncology initiates Phase II registration clinical trial (KN046-205) for bispecific antibody KN046 with a successful researchers\u2019 conference","author":"Alphamab Oncology","year":"2020"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6557"},{"key":"cit0118","unstructured":"F Hoffman-La Roche Ltd. Roche provides an update on the phase III COVACTA trial of Actemra\/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. July 29, 2020 press release. Accessed November 11, 2020. www.roche.com\/investors\/updates\/inv-update-2020-07-29.htm"},{"key":"cit0119","unstructured":"F Hoffman-La Roche Ltd. Roche\u2019s phase III EMPACTA study showed Actemra\/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. September 18, 2020 press release. Accessed November 11. www.roche.com\/investors\/updates\/inv-update-2020-09-18.htm."},{"key":"cit0120","unstructured":"Novartis. Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar\u00ae + Mekinist\u00ae in advanced melanoma. August 22, 2020 press release. Accessed October 26, 2020. www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma."},{"key":"cit0121","unstructured":"F. Hoffman-La Roche Ltd. Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis. August 10, 2020 press release. Accessed September 24, 2020. https:\/\/www.roche.com\/investors\/updates\/inv-update-2020-08-10.htm."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2020.1860476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:51:45Z","timestamp":1659941505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2020.1860476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/19420862.2020.1860476"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2020.1860476","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1860476"}}